» Articles » PMID: 38664245

Bergapten Enhances Mitophagy to Regulate Intestinal Barrier and Th17/Treg Balance in Mice with Crohn's Disease-like Colitis Via PPARγ/NF-κB Signaling Pathway

Overview
Specialty Pharmacology
Date 2024 Apr 25
PMID 38664245
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to investigate whether bergapten (BG), a furanocoumarin phytohormone, holds promise for Crohn's disease (CD)-like colitis treatment and to preliminarily explore its potential mechanisms. 2,4,6-Trinitrobenzenesufonic acid (TNBS)-treated mice were applied to establish an in vivo research model, and BG was administered with different concentrations. The status of mice in each group was evaluated by disease activity index (DAI), and the severity was evaluated by pathological sections. The intestinal barrier was assessed by measuring in vivo intestinal permeability, peripheral blood intestinal fatty acid-binding protein (I-FABP) levels, epithelial resistance values, and tight junction protein levels. Markers were then used to assess Th17/Treg levels, mitophagy, and the peroxisome proliferator-activated receptor (PPAR)γ/ nuclear factor kappa B (NF-κB) signaling pathway. BG significantly reduced colon tissue damage in a concentration-dependent manner. DAI scores showed that the loose feces, occult blood, and weight loss of mice in the BG treatment were significantly reduced, and pathological section results revealed reduced inflammatory infiltration and fibrosis. Reduced serum FITC-dextran and I-FABP and increased levels of epithelial resistance and tight junction proteins support that the intestinal barrier was protected upon BG. The proportion of Th17 in mesenteric lymph nodes increased while Treg decreased in the model group. BG treatment effectively reduced the conversion of Treg to Th17. Additionally, BG was found to enhance mitophagy and activate the PPARγ/NF-κB signaling. BG demonstrates promising effects in ameliorating intestinal barrier damage and Th17/Treg imbalance in a murine model of CD-like colitis, while also promoting intracellular mitophagy. The PPARγ/NF-κB signaling pathway may serve as a key mediator of BG's regulatory mechanisms.

References
1.
Akhter S, Tasnim F, Islam M, Rauf A, Mitra S, Emran T . Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases. Curr Pharm Des. 2023; 29(26):2078-2090. DOI: 10.2174/1381612829666230904150808. View

2.
Alrubia S, Al-Majdoub Z, Achour B, Rostami-Hodjegan A, Barber J . Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters. J Pharm Sci. 2022; 111(10):2917-2929. DOI: 10.1016/j.xphs.2022.07.012. View

3.
Aslam H, Khan A, Qazi N, Ali F, Hassan S, Bungau S . Pharmacological basis of bergapten in gastrointestinal diseases focusing on H/K ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs. Front Pharmacol. 2022; 13:1005154. PMC: 9709249. DOI: 10.3389/fphar.2022.1005154. View

4.
Cheng W, Ren Y, Lu M, Xu L, Gao J, Chen D . Palmitoylation in Crohn's disease: Current status and future directions. World J Gastroenterol. 2022; 27(48):8201-8215. PMC: 8717020. DOI: 10.3748/wjg.v27.i48.8201. View

5.
Choi S, Shin Y, Lee J, Yoon Y, Kim J, Sung M . -Acetylglucosamine and its dimer ameliorate inflammation in murine colitis by strengthening the gut barrier function. Food Funct. 2023; 14(18):8533-8544. DOI: 10.1039/d3fo00282a. View